7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Sagimet Biosciences Inc.
(NASDAQ:SGMT) 

SGMT stock logo

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors to treat non-alcoholic steatohepatitis, acne, and various cancers. The company's lead drug candidate is Denifanstat, a fatty acid synthase inhibitor for the treatm...

Founded: 2006
Sector: TECHNOLOGY
Industry: GENERAL

Share this website to your friends
Sagimet Biosciences Op Cashflow Per Share ttm
202311 202312 202401 202402 202403 202404 -1.33-1.14-0.95-0.76-0.57-0.38-0.190
Sagimet Biosciences Free Cashflow Per Share ttm
202311 202312 202401 202402 202403 202404 -1.33-1.14-0.95-0.76-0.57-0.38-0.190
Sagimet Biosciences Cash Per Share ttm
202311 202312 202401 202402 202403 202404 00.81.62.43.244.85.6
Sagimet Biosciences P/S ratio ttm
202311 202312 202401 202402 202403 202404 01835.9953.9971.9989.98107.98125.97
Sagimet Biosciences (GAAP) P/E ratio ttm
202311 202312 202401 202402 202403 202404 -6.79-5.82-4.85-3.88-2.91-1.94-0.970
Sagimet Biosciences P/B ratio ttm
202311 202312 202401 202402 202403 202404 00.270.530.81.071.331.61.87
No extra charts and metrics for this ticker.